3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Warts
2
Melanoma
2
Hyperthermia
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Interventions
Bevacizumab
40
Paclitaxel
35
Carboplatin
28
pembrolizumab
21
Cyclophosphamide
15
Specimen Handling
14
Cisplatin
13
olaparib
11
Blood Specimen Collection
11
niraparib
10
fludarabine
10
Magnetic Resonance Spectroscopy
9
Drug Therapy
9
liposomal doxorubicin
8
Topotecan
8
Taxes
8
Gemcitabine
8
Biopsy
8
Fulvestrant
7
Doxorubicin
6
cemiplimab
5
abemaciclib
5
Surveys and Questionnaires
5
Standard of Care
5
Injections
5
Fluorouracil
5
Cytoreduction Surgical Procedures
5
trastuzumab deruxtecan
4
mirvetuximab soravtansine
4
aldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ovarian Neoplasms
×
Solutions
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled